Combining structure and function to evaluate glaucomatous progression: implications for the design of clinical trials

Area of Science:

• Ophthalmology
• Neuroscience
• Clinical Trial Design

Background:

• Accurate assessment of glaucomatous progression is crucial for designing clinical trials of neuroprotective therapies.
• Current diagnostic tests have limitations in reliably detecting disease progression and estimating rates of change.
• Combining structural and functional tests is essential for robust endpoint detection in glaucoma research.

Purpose of the Study:

• To evaluate a novel approach for estimating retinal ganglion cell loss by integrating structural and functional tests.
• To determine if this combined approach offers improved performance over conventional, isolated parameters for glaucoma assessment.
• To establish the utility of this method as a reliable outcome measure in clinical trials for glaucoma.

Main Methods:

• Utilizing a recent approach that combines both structural and functional testing modalities.
• Assessing the performance of this integrated method for diagnosing, staging, and detecting glaucoma progression.
• Comparing the efficacy of the combined approach against isolated parameters from conventional glaucoma tests.

Main Results:

• The combined structural and functional testing approach demonstrated superior performance compared to isolated conventional tests.
• This integrated method shows promise for more reliable diagnosis, staging, and progression detection in glaucoma.
• The approach facilitates more accurate estimation of retinal ganglion cell loss rates.

Conclusions:

• A combined structural and functional testing strategy is essential for reliable glaucoma progression assessment.
• This integrated approach can potentially lead to shorter clinical trials with smaller sample sizes.
• The method is a valuable outcome measure for evaluating neuroprotective therapies in glaucoma clinical trials.